1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI) | Zendy

AI Assistant Blog Pricing

1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.